BRIM Biotechnology, Inc. (TPE:6885)

Market Cap	3.78B -2.5%
Revenue (ttm)	3.17M +1,933.3%
Net Income	-387.70M
EPS	-3.00
Shares Out	133.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	473,155
Average Volume	555,352
Open	28.60
Previous Close	28.40
Day's Range	27.60 - 28.65
52-Week Range	20.05 - 41.30
Beta	1.05
RSI	49.19
Earnings Date	Mar 17, 2026

About BRIM Biotechnology

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company’s lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that ha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 32
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6885

Financial Performance

In 2024, BRIM Biotechnology's revenue was 333,000, an increase of 270.00% compared to the previous year's 90,000. Losses were -315.47 million, -54.15% less than in 2023.